Nykode Therapeutics

🚀 Exciting News from Nykode Therapeutics! 🚀   We are thrilled to announce that the United States Patent and Trademark Office has issued a key patent for our fully individualized neoantigen-based vaccine, VB10.NEO. This patent, which is set to expire on January 5, 2037, marks a significant milestone in our mission to develop innovative cancer immunotherapies.   VB10.NEO is designed to target neoantigens—proteins generated by tumor-specific mutations—making it a promising treatment for locally advanced or metastatic solid tumors.   As Michael Engsig, CEO of Nykode, aptly stated, "The granting of this patent is a testament to the world-class innovation taking place in Nykode's labs. We remain dedicated to pushing the boundaries of what's possible in medicine, bringing hope to patients and their families around the globe."   We're proud to be at the forefront of cancer treatment innovation and look forward to continuing our work to make a difference in the lives of patients worldwide.   #CancerResearch #Immunotherapy #Innovation #VB10NEO #Patents #Biotech #HealthcareInnovation

🚀 Exciting news from Nykode!   We are thrilled to share that Jefferies, a globally recognized full-service investment bank, has initiated coverage on Nykode with a "Buy" rating and set a target price of NOK17.5. 🌟   This marks the second time a New York-based investment bank has initiated coverage on Nykode. 📈   A total of six banks are now covering Nykode, all recommending a "Buy" rating. This strong endorsement underscores the confidence and potential seen in our Nykode technology platform.   Stay tuned for more updates as we continue our journey. 💼🔬   #Nykode #Jefferies #BuyRating #Innovation #Biotech

We are delighted to share the latest podcast (in Norwegian) from Radforsk featuring our very own Michael Engsig and Agnete Fredriksen. They reflect on a busy six months of breakthroughs and exciting data, and look ahead to an equally promising year.

🌟 Nykode's Brian Weinert is participating in the Nature Conferences: Cancer Immunotherapy meeting in Boston, MA, from June 10th through June 12th. Our team is presenting research on our innovative cancer vaccine technology, which incorporates advanced mRNA-lipid nanoparticle (LNP) formats.   🔍 Our study, featured in poster presentation # 2-22 on June 11th, compares an APC-targeted neoantigen mRNA vaccine to an untargeted version across various mRNA-LNP doses. The APC-targeted vaccine consistently induced a stronger and broader immune response. In a mouse model of colorectal cancer, it also demonstrated superior tumor control and significantly better survival outcomes than the untargeted mRNA vaccine.   📊 For more details, please visit our poster on our website: https://lnkd.in/eh4Nrx76   #CancerResearch #Immunotherapy #Biotechnology #NatureConf #NatureCancer #NatureMedicine #NatImmunol   https://lnkd.in/eFMJeAJW

Nykode is pleased to announce an expansion of our collaboration with Merck (Merck & Co., Inc., Rahway, NJ, USA), focusing on the advancement of VB10.16 in combination with MSD’s KEYTRUDA® (pembrolizumab) in a Phase 2 trial for HPV16-positive high-risk cervical cancer. This partnership reflects our shared dedication to developing new immunotherapy treatments for cancer.    For more details on this collaboration, please read the full press release https://lnkd.in/eK8v6G-A.   We look forward to continuing our work with MSD to explore potential solutions for those affected by this disease.    #MSD #Oncology #ClinicalTrials #Immunotherapy #HealthcareInnovation

Thanks Catherine Shaffer for the great article!

Today, we had the pleasure of participating in a webcast hosted by Geir Hiller Holom from DNB Markets, where our CEO, Michael Engsig, and Klaus Edvardsen, our Chief Research and Development Officer, discussed our pioneering VB10.16 program. Designed to make complex scientific information accessible, this session is a must-watch for anyone interested in the latest advancements in cancer treatment.   🎥 Watch the recording (in Norwegian) now! Dive into the details of our VB10.16 program at your convenience. https://lnkd.in/exFGeJhU   Let’s demystify science together and explore the potential of VB10.16.   #CancerResearch #Biotech #MedicalInnovation #DNBWebcast

Nykode's Chief Scientific Officer and Co-founder, Agnete Fredriksen, will be presenting at the 7th International Neoantigen Summit in Amsterdam from April 29th to May 1st. Agnete will share new preclinical data from our collaboration with Genentech, focusing on the differentiation of our proprietary vaccine technology.   Details for Nykode Therapeutics’ presentation are as follows:   🔹 Title: Optimizing RNA/DNA-Based Vaccine Design by Identifying Key Characteristics to Ensure Success of the Therapy 🕒 Time & Date: 10.00am CET, May 1, 2024   #NeoantigenSummit #Immunotherapy #VaccineTechnology #BiotechInnovation

Join our very own Clinical Supply Manager, Danielle L. Hagen, as she shares valuable insights at this week's 3rd BioPharma Supply Chain & Logistics Nexus. Don’t miss out on learning about the intricacies and innovations in personalized cancer vaccine supply chains.   See you there! #BioPharmaNexusConference #BioPharma #SupplyChain

🚀 Exciting News from Nykode! 🚀   Today marks a significant milestone for Nykode Therapeutics as we initiate our potential registrational trial of VB10.16 in HPV16-positive cervical cancer, in collaboration with The GOG Foundation, Inc. This important trial targets patients with HPV16-positive recurrent or metastatic cervical cancer who face significant unmet medical needs.   VB10.16 represents our commitment to innovative immunotherapy solutions, aiming to improve cancer care and expand treatment options for challenging conditions.   We are grateful for the support from The GOG Foundation, Inc, the dedication of our team, and the participation of the patients.   Stay tuned for updates on this important trial. We're committed to making strides in the fight against cancer.   #CancerResearch #Immunotherapy #HPV16 #CervicalCancer